Email Alert RSS
Volume 11 Issue 4
Jul.  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(4): 395-401
Ming CUI, Ou WANG, Quan LIAO. Advances in Diagnosis and Surgical Treatment of Primary Hyperparathyroidism[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 395-401. doi: 10.3969/j.issn.1674-9081.2020.04.007
Citation: Ming CUI, Ou WANG, Quan LIAO. Advances in Diagnosis and Surgical Treatment of Primary Hyperparathyroidism[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 395-401. doi: 10.3969/j.issn.1674-9081.2020.04.007
shu

Advances in Diagnosis and Surgical Treatment of Primary Hyperparathyroidism

doi: 10.3969/j.issn.1674-9081.2020.04.007
  • 1.

    Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: LIAO Quan  Tel: 86-10-69152600, E-mail:lqpumc@126.com
  • Received Date: 2020-02-10
  • Publish Date: 2020-07-30
    Abstract
  • Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia, which is due to excessive secretion of parathyroid hormone (PTH) from one or several parathyroid glands. With the tests of serum calcium and PTH being routinely employed, the incidence of PHPT has distinctly increased and PHPT has become a common endocrine disorder. The concept of diagnosis and treatment for PHPT has been developing continuously. Most cases of PHPT are sporadic, while 5%-10% of cases are hereditary. In this literature, we reviewed the advances in diagnosis and surgical treatment of PHPT.
    • FullText(HTML)
  • loading
    • References(40)
  • [1] Bilezikian JP, Bandeira L, Khan A, et al. Hyperparathyroidism[J]. Lancet, 2018, 391:168-178. doi:  10.1016/S0140-6736(17)31430-7
    [2] Walker MD, Silverberg SJ. Primary hyperparathyroidism[J]. Nat Rev Endocrinol, 2018, 14:115-125. doi:  10.1038/nrendo.2017.104
    [3] 中国研究型医院学会甲状旁腺及骨代谢疾病专业委员会, 中国研究型医院学会罕见病分会.甲状旁腺癌诊治的专家共识[J].中华内分泌代谢杂志, 2019, 35:361-368. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnfmdx201905002
    [4] 中华医学会骨质疏松和骨矿盐疾病分会, 中华医学会内分泌分会代谢性骨病学组.原发性甲状旁腺功能亢进症诊疗指南[J].中华骨质疏松和骨矿盐疾病杂志, 2014, 7:187-198. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgzsshgkyjbzz201403003
    [5] Lavryk OA, Siperstein AE. Use of Calcium and Parathyroid Hormone Nomogram to Distinguish Between Atypical Primary Hyperparathyroidism and Normal Patients[J]. World J Surg, 2017, 41:122-128. doi:  10.1007/s00268-016-3716-6
    [6] Silva BC, Cusano NE, Bilezikian JP. Primary hyperparathyroidism[J]. Best Pract Res Clin Endocrinol Metab, 2018:101247. doi:  10.1016/j.beem.2018.09.013
    [7] Yu N, Donnan PT, Murphy MJ, et al. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK[J]. Clin Endocrinol (Oxf), 2009, 71:485-493. doi:  10.1111/j.1365-2265.2008.03520.x
    [8] Piketty ML, Prie D, Sedel F, et al. High-dose biotin therapy leading to false biochemical endocrine profiles:validation of a simple method to overcome biotin interference[J]. Clin Chem Lab Med, 2017, 55:817-825. doi:  10.1515/cclm-2016-1183
    [9] Cetani F, Pardi E, Marcocci C. Parathyroid Carcinoma[J]. Front Horm Res, 2019, 51:63-76.
    [10] Cui M, Hu Y, Zheng B, et al. Cancer-derived Immunoglobulin G:A Novel Marker for Differential Diagnosis and Relapse Prediction in Parathyroid Carcinoma[J]. Clin Endocrinol (Oxf), 2020, 92:461-467. doi:  10.1111/cen.14158
    [11] Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism:Summary Statement from the Fourth International Workshop[J]. J Clin Endocrinol Metab, 2014, 99:3561-3569. doi:  10.1210/jc.2014-1413
    [12] Liu Y, Dang Y, Huo L, et al. Preoperative localisation of adenomas in primary hyperparathyroidism:the value of11C-choline PET/CT in patients with negative or discordant ultrasonography and 99mTc-Sesta-MIBI-SPECT/CT[J]. J Nucl Med, 2020, 61:584-589. doi:  10.2967/jnumed.119.233213
    [13] Woisetschläger M, Gimm O, Johansson K, et al. Dual energy 4D-CT of parathyroid adenomas not clearly localized by sestamibi scintigraphy and ultrasonography-a retrospective study[J]. Eur J Radiol, 2020, 124:108821. doi:  10.1016/j.ejrad.2020.108821
    [14] 张翔, 胡亚, 王梦一, 等.原发性甲状旁腺功能亢进症的术前诊断与外科治疗策略[J].中华内分泌外科杂志, 2018, 12:274-277. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=nfmwk201804003
    [15] Bhangu JS, Riss P. The role of intraoperative parathyroid hormone (IOPTH) determination for identification and surgical strategy of sporadic multiglandular disease in primary hyperparathyroidism (pHPT)[J]. Best Pract Res Clin Endocrinol Metab, 2019, 33:101310. doi:  10.1016/j.beem.2019.101310
    [16] Thielmann A, Kerr P. Validation of selective use of intraoperative PTH monitoring in parathyroidectomy[J]. J Otolaryngol Head Neck Surg, 2017, 46:10. doi:  10.1186/s40463-017-0188-0
    [17] Najafian A, Kahan S, Olson MT, et al. Intraoperative PTH May Not Be Necessary in the Management of Primary Hyperparathyroidism Even with Only One Positive or Only Indeterminate Preoperative Localization Studies[J]. World J Surg, 2017, 41:1500-1505. doi:  10.1007/s00268-017-3871-4
    [18] Singh Ospina NM, Rodriguez-Gutierrez R, Maraka S, et al. Outcomes of Parathyroidectomy in Patients with Primary Hyperparathyroidism:A Systematic Review and Meta-analysis[J]. World J Surg, 2016, 40:2359-2377. doi:  10.1007/s00268-016-3514-1
    [19] Bakkar S, Materazzi G, Biricotti M, et al. Minimally invasive video-assisted thyroidectomy (MIVAT) from A to Z[J]. Surg Today, 2016, 46:255-259. doi:  10.1007/s00595-015-1241-0
    [20] Arora A, Garas G, Tolley N. Robotic Parathyroid Surgery:Current Perspectives and Future Considerations[J]. ORL J Otorhinolaryngol Relat Spec, 2018, 80:195-203. doi:  10.1159/000488355
    [21] Cetani F, Saponaro F, Borsari S, et al. Familial and Hereditary Forms of Primary Hyperparathyroidism[J]. Front Horm Res, 2019, 51:40-51.
    [22] Cristina E, Alberto F. Management of familial hyperparathyroidism syndromes:MEN1, MEN2, MEN4, HPT-Jaw tumour, Familial isolated hyperparathyroidism, FHH, and neonatal severe hyperparathyroidism[J]. Best Pract Res Clin Endocrinol Metab, 2018, 32:861-875. doi:  10.1016/j.beem.2018.09.010
    [23] Delellis RA, Mangray S. Heritable forms of primary hyperparathyroidism:a current perspective[J]. Histopathology, 2018, 72:117-132. doi:  10.1111/his.13306
    [24] Giusti F, Cianferotti L, Boaretto F, et al. Multiple endocrine neoplasia syndrome type 1:institution, management, and data analysis of a nationwide multicenter patient database[J]. Endocrine, 2017, 58:349-359. doi:  10.1007/s12020-017-1234-4
    [25] Vannucci L, Marini F, Giusti F, et al. MEN1 in children and adolescents:Data from patients of a regional referral center for hereditary endocrine tumors[J]. Endocrine, 2018, 59:438-448. doi:  10.1007/s12020-017-1322-5
    [26] Di Meo G, Sgaramella LI, Ferraro V, et al. Parathyroid carcinoma in multiple endocrine neoplasm type 1 syndrome:case report and systematic literature review[J]. Clin Exp Med, 2018, 18:585-593. doi:  10.1007/s10238-018-0512-7
    [27] Pieterman CR, van Hulsteijn LT, den Heijer M, et al. Primary hyperparathyroidism in MEN1 patients:a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype[J]. Ann Surg, 2012, 255:1171-1178. doi:  10.1097/SLA.0b013e31824c5145
    [28] Udelsman R, åkerström G, Biagini C, et al. The Surgical Management of Asymptomatic Primary Hyperparathyroidism:Proceedings of the Fourth International Workshop[J]. J Clin Endocrinol Metab, 2014, 99:3595-3606. doi:  10.1210/jc.2014-2000
    [29] Romei C, Pardi E, Cetani F, et al. Genetic and clinical features of multiple endocrine neoplasia types 1 and 2[J]. J Oncol, 2012:705036.
    [30] Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma[J]. Nat Rev Endocrinol, 2016, 12:192-202. doi:  10.1038/nrendo.2016.11
    [31] Machens A, Lorenz K, Dralle H. Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2:need for age-adjusted biochemical screening[J]. J Clin Endocrinol Metab, 2013, 98:E336-E345. doi:  10.1210/jc.2012-3192
    [32] O'Riordain DS, O'Brien T, Grant CS, et al. Surgical management of primary hyperparathyroidism in multiple endocr-ine neoplasia types 1 and 2[J]. Surgery, 1993, 114:1031-1039.
    [33] Guerin C, Romanet P, Taieb D, et al. Looking beyond the thyroid:advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms[J]. Endocr Relat Cancer, 2018, 25:T15-T28. doi:  10.1530/ERC-17-0266
    [34] Alrezk R, Hannah-Shmouni F, Stratakis CA. MEN4 and CDKN1B mutations:the latest of the MEN syndromes[J]. Endocr Relat Cancer, 2017, 24:T195-T208. doi:  10.1530/ERC-17-0243
    [35] Lee M, Pellegata NS. Multiple endocrine neoplasia syndro-mes associated with mutation of p27[J]. J Endocrinol Invest, 2013, 36:781-787.
    [36] Torresan F, Iacobone M. Clinical Features, Treatment, and Surveillance of Hyperparathyroidism-Jaw Tumor Syndrome: An Up-to-Date and Review of the Literature[J]. Int J Endocrinol, 2019.doi: 10.1155/2019/1761030.[Epubaheadofprint].
    [37] Mehta A, Patel D, Rosenberg A, et al. Hyperparathyroidism-jaw tumor syndrome:Results of operative management[J]. Surgery, 2014, 156:1315-1325. doi:  10.1016/j.surg.2014.08.004
    [38] Iacobone M, Camozzi V, Mian C, et al. Long-Term Outcomes of Parathyroidectomy in Hyperparathyroidism-Jaw Tumor Syndrome:Analysis of Five Families with CDC73 Mutations[J]. World J Surg, 2020, 44:508-516. doi:  10.1007/s00268-019-05156-y
    [39] Pardi E, Borsari S, Saponaro F, et al. Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features[J]. PLoS One, 2017, 12:e186485.
    [40] Simonds WF, James-Newton LA, Agarwal SK, et al. Familial isolated hyperparathyroidism:clinical and genetic characteristics of 36 kindreds[J]. Medicine (Baltimore), 2002, 81:1-26. doi:  10.1097/00005792-200201000-00001
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (600) PDF downloads(132) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return